Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication

Launched by ASIAN INSTITUTE OF GASTROENTEROLOGY, INDIA · Apr 28, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment called vonoprazan to see how it compares to standard triple therapy for eradicating Helicobacter pylori (H. pylori) infections. H. pylori is a type of bacteria that can cause stomach problems, including ulcers and even stomach cancer. The trial aims to find a more effective treatment option, especially because many people are facing issues with antibiotic resistance, which makes it harder to treat these infections successfully.

To be eligible for this study, participants need to be adults between 18 and 80 years old who have symptoms like stomach discomfort or gastroesophageal reflux disease (GERD) and have tested positive for H. pylori. They should not have taken certain medications recently or have specific health issues that could interfere with the treatment. If someone joins the trial, they can expect to receive the study medication and be monitored for any side effects, contributing to important research that could improve treatment for H. pylori infections in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (18 years - 80 years)
• • Patient visiting clinic with dyspepsia, GERD, or non-bleeding peptic ulcer
• • 13C-urea breath test (UBT) positive/ Rapid urease test positive (RUT) on endoscopic biopsy
• • Off PPIs for 2 weeks
• Exclusion Criteria:
• • Penicillin allergy
• • Recent use of antibiotics in the past 1 month
• • Previous H. pylori therapy
• • Intestinal metaplasia, gastric cancer, bleeding peptic ulcer
• • Patient who is unable to understand study protocol or not consenting
• • Pregnancy, lactation
• • Patient on anticoagulation, NSAIDs
• • Patient using drugs with interactions with vonoprazan, amoxicillin, clarithromycin or PPIs
• • Cirrhosis, Chronic kidney disease, chronic lung disease